ESTRO 2024 - Abstract Book

S2164

Clinical - Upper GI

ESTRO 2024

Radiation therapy was delivered at a total dose of 60 Gy in 30 fractions to the esophagus and 70 Gy in 35 fractions to the pharynx, plus elective nodal irradiation to the locoregional area at a total dose of 40 Gy in 20 fractions. All irradiation was delivered via three-dimensional conformal radiation therapy. If feasible, systemic chemotherapy was administered concurrently with RT. The regimen of chemotherapy was determined based on which cancer was more clinically advanced; cisplatin and 5-fluorouracil were used for patients with more advanced esophageal cancer and either cisplatin, docetaxel, or TS1 was used for patients with more advanced pharyngeal cancer. Clinical stage was determined according to the 8th edition of the Union for International Cancer Control Tumor Node Metastasis classification. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 5.0. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan – Meier method.

Results:

The duration of the observation period was a median of 15 months (range: 3 – 164 months). The hypopharynx was the subfield of pharyngeal cancer in 19 patients (90%), while the oropharynx was the subfield in 2 patients (10%). The thoracic esophagus was the subfield of esophageal cancer in all patients (100%). Squamous cell carcinoma was the histological type found in both the pharyngeal and esophageal cancers. When comparing clinical stages, 11 patients (52%) had more advanced pharyngeal cancer than esophageal cancer, 7 (33%) had more advanced esophageal cancer than pharyngeal cancer, and 3 (14%) had cancers at the same clinical stage. Twenty patients (95%) received systemic chemotherapy concurrently with radiation therapy.